Arcus Biosciences (RCUS) Expected to Announce Earnings on Tuesday

Key Points

• Arcus Biosciences is expected to report Q3 2026 results after market close on October 27. Analysts forecast a loss of $0.8824 per share and revenue of $8.78 million; the earnings call is scheduled for November 3 at 4:00 p.m. ET.
• In its previous quarter, Arcus reported a loss of $0.72 per share, beating estimates for a $0.89 loss, while revenue of $41 million exceeded forecasts but fell 74.4% year over year.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $38.55, compared with the stock’s opening price of $22.14; the company remains unprofitable, with a negative net margin of 393.16%.

Arcus Biosciences (NYSE:RCUS - Get Free Report) will likely be releasing its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect the company to announce earnings of ($0.8824) per share and revenue of $8.78 million for the quarter. Individuals can find conference call details on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:00 PM ET.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($0.72) earnings per share for the quarter, beating analysts' consensus estimates of ($0.89) by $0.17. Arcus Biosciences had a negative net margin of 393.16% and a negative return on equity of 89.54%. The business had revenue of $41.00 million during the quarter, compared to the consensus estimate of $21.98 million. The company's quarterly revenue was down 74.4% compared to the same quarter last year. On average, analysts expect Arcus Biosciences to post ($3.52) EPS for the current fiscal year and ($3.15) EPS for the next fiscal year.

Arcus Biosciences Stock Up 0.1%

RCUS stock opened at $22.14 on Tuesday. Arcus Biosciences has a twelve month low of $16.35 and a twelve month high of $31.74. The company has a quick ratio of 3.82, a current ratio of 3.82 and a debt-to-equity ratio of 0.22. The firm has a market cap of $2.82 billion, a PE ratio of -5.68 and a beta of 0.94. The business has a 50 day moving average of $26.83 and a 200 day moving average of $26.24.

Insider Activity at Arcus Biosciences

In related news, CAO Alexander Azoy sold 2,827 shares of the company's stock in a transaction on Friday, August 21st. The stock was sold at an average price of $30.00, for a total transaction of $84,810.00. Following the completion of the sale, the chief accounting officer owned 39,581 shares in the company, valued at approximately $1,187,430. This represents a 6.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

RCUS has been the subject of several analyst reports. Wall Street Zen upgraded Arcus Biosciences from a "sell" rating to a "hold" rating in a report on Saturday, October 3rd. Wedbush reiterated an "outperform" rating and issued a $43.00 price target on shares of Arcus Biosciences in a research note on Wednesday, September 30th. William Blair began coverage on shares of Arcus Biosciences in a research note on Friday. They issued an "outperform" rating on the stock. The Goldman Sachs Group reissued a "buy" rating and set a $42.00 price objective on shares of Arcus Biosciences in a research report on Friday, August 7th. Finally, Morgan Stanley set a $23.00 price objective on shares of Arcus Biosciences in a research note on Monday, August 10th. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $38.55.

About Arcus Biosciences

Arcus Biosciences, Inc is a biopharmaceutical company focused on discovering and developing medicines for the treatment of cancer. The company uses a proprietary research platform to develop small-molecule and antibody-based therapies designed to target biological mechanisms involved in tumor growth and immune-system regulation.

Arcus' oncology pipeline has included investigational therapies such as zimberelimab, an anti-PD-1 antibody; domvanalimab, an anti-TIGIT antibody; quemliclustat, a CD73 inhibitor; and etrumadenant, an adenosine receptor antagonist.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.